14:46 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Arsanis discontinues Phase II of lead anti-infective

Arsanis Inc. (NASDAQ:ASNS) discontinued a double-blind, international Phase II trial of lead candidate ASN100 to prevent Staphylococcus aureus pneumonia after a futility analysis showed that the candidate was unlikely to meet its primary endpoint. In...
16:49 , Jun 28, 2018 |  BC Extra  |  Clinical News

Arsanis discontinues Phase II of lead anti-infective, shares plummet

Arsanis Inc. (NASDAQ:ASNS) discontinued a Phase II trial of lead candidate ASN100 to prevent Staphylococcus aureus pneumonia after a futility analysis showed that the candidate was unlikely to meet its primary endpoint. The company's shares...
19:16 , Feb 21, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggest depleting asparagine with l-asparaginase or ASNS inhibition could help treat metastatic breast cancer. In an allogeneic mouse model of metastatic breast cancer, shRNA targeting ASNS decreased the number of...
00:43 , Jan 13, 2018 |  BioCentury  |  Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market...
21:51 , Dec 5, 2017 |  BC Extra  |  Company News

Pellini joins Section 32

Section 32 named Michael Pellini managing partner. Pellini, who is chairman of cancer molecular profiling company Foundation Medicine Inc. (Cambridge, Mass.), will lead healthcare investments for the firm. Section 32’s portfolio includes infectious disease companies...
19:45 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Arsanis raises $60M IPO and private placement

On Nov. 15, Arsanis Inc. (NASDAQ:ASNS) raised $60 million in an IPO on NASDAQ and a concurrent private placement. The company raised $40 million through the sale of 4 million shares in the IPO underwritten...
18:31 , Nov 16, 2017 |  BC Extra  |  Financial News

Arsanis rises on $60M IPO and private placement

Arsanis Inc. (NASDAQ:ASNS) jumped $4.03 (40%) to $14.03 on its first day of trading Thursday after raising $60 million in an IPO on NASDAQ and a concurrent private placement. The company raised $40 million through...
18:50 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

Erytech reports additional Phase IIb data for eryaspase in pancreatic cancer

In September, Erytech Pharma S.A. (Euronext:ERYP) reported additional data from a Phase IIb trial to treat progressive metastatic pancreatic cancer showing that second-line treatment with eryaspase (Graspa, ERY-ASP, ERY001) plus standard of care (SOC) gemcitabine...
05:15 , Mar 31, 2017 |  BC Week In Review  |  Clinical News

Eryaspase: Ph IIb data

Top-line data from about 98 patients with progressive metastatic pancreatic cancer and low levels of asparagine synthetase (ASNS) in an open-label, French Phase IIb trial showed that second-line treatment with eryaspase plus standard of care...
00:50 , Mar 28, 2017 |  BC Extra  |  Clinical News

Erytech soars on pancreatic cancer readout

Erytech Pharma S.A. (Euronext:ERYP) rose €10.70 (75%) to €25 on Monday after it said Graspa eryaspase met the co-primary endpoints in a French Phase IIb study to treat metastatic pancreatic cancer in a second-line setting....